251 related articles for article (PubMed ID: 17214585)
1. Targeting fibrosis in systemic sclerosis.
Lafyatis R
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):395-400. PubMed ID: 17214585
[TBL] [Abstract][Full Text] [Related]
2. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
Hasegawa M; Takehara K
Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
[TBL] [Abstract][Full Text] [Related]
3. New developments in the pathogenesis of systemic sclerosis.
Sakkas LI
Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
[TBL] [Abstract][Full Text] [Related]
4. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
[TBL] [Abstract][Full Text] [Related]
5. Innate immunity and inflammation in systemic sclerosis.
Lafyatis R; York M
Curr Opin Rheumatol; 2009 Nov; 21(6):617-22. PubMed ID: 19633559
[TBL] [Abstract][Full Text] [Related]
6. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
[TBL] [Abstract][Full Text] [Related]
8. Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis.
Fang D; Chen B; Lescoat A; Khanna D; Mu R
Nat Rev Rheumatol; 2022 Dec; 18(12):683-693. PubMed ID: 36352098
[TBL] [Abstract][Full Text] [Related]
9. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
[TBL] [Abstract][Full Text] [Related]
10. Innovative antifibrotic therapies in systemic sclerosis.
Beyer C; Distler O; Distler JH
Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
[TBL] [Abstract][Full Text] [Related]
11. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
13. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.
Abraham D; Lescoat A; Stratton R
Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
15. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
[TBL] [Abstract][Full Text] [Related]
16. Targeting vascular disease in systemic sclerosis.
Kowal-Bielecka O
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
[TBL] [Abstract][Full Text] [Related]
17. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
Di Benedetto P; Liakouli V; Ruscitti P; Berardicurti O; Carubbi F; Panzera N; Di Bartolomeo S; Guggino G; Ciccia F; Triolo G; Cipriani P; Giacomelli R
Arthritis Res Ther; 2018 Oct; 20(1):223. PubMed ID: 30285896
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
19. 1,25OH-Vitamin D3 and IL-17 Inhibition Modulate Pro-Fibrotic Cytokines Production in Peripheral Blood Mononuclear Cells of Patients with Systemic Sclerosis.
Corrado A; Rotondo C; Sanpaolo ER; Altomare A; Maruotti N; Cici D; Cantatore FP
Int J Med Sci; 2022; 19(5):867-877. PubMed ID: 35693738
[No Abstract] [Full Text] [Related]
20. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]